Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam possesses a wide therapeutic index[L8615,A185918] and little-to-no potential to produce, or be subject to, pharmacokinetic interactions[L8606,L8600,L8615] - these characteristics make it a desirable choice over other AEDs, a class of drugs notorious for having generally narrow therapeutic indexes and a propensity for involvement in drug interactions.[A185927]
Synonyms
Levetiracetame
Levetiracetamum
Levetiracetam
Lévétiracetam
Brand Names
Dom-levetiracetam
Elepsia XR
Pdp-levetiracetam
Pro-levetiracetam - 750
Auro-levetiracetam
PHL-levetiracetam
Mint-levetiracetam Solution
Levetiracetam Accord
Tva-levetiracetam
LEVETIRACETAM Extended-release
Teva-levetiracetam
Levetiracetam 250 mg
PMS-levetiracetam
Roweepra XR
Levetiractam
Jamp-levetiracetam
Ag-levetiracetam
Ava-levetiracetam
Nat-levetiracetam
Nra-levetiracetam
Levetiracetam Actavis
Levetiracetam Extended-Release
Levetiracetam in Sodium Chloride
Levetiracetam
Levetiracetam 1000 mg
Matever
Levetiracetam Extended Release
Ach-levetiracetam
Keppra
Roweepra
Levertiracetam
Levetiracetam Teva
Pro-levetiracetam - 500
Levetiracetam 750 mg
Novo-levetiracetam
Jamp Levetiracetam Tablets
Torrent-levetiracetam
Van-levetiracetam
Levetiracetam Injection USP
Levetiracetam Hospira
Pharma-levetiracetam
Spritam
Elepsia XR 1500 mg
Ran-levetiracetam
Elepsia XR 1000 mg
Priva-levetiracetam
Levetiracetam Sun
M-levetiracetam
Sandoz Levetiracetam
Mint-levetiracetam
Riva-levetiracetam
Levetiracetam Micro
Levetiracetam extended-release
Levetiracetam Levetiracetam
LEVETIRACETAM solution
Abbott-levetiracetam
Levetiracetam Actavis Group
Bio-levetiracetam
Levetiracetam Ratiopharm
Keppra XR
Pro-levetiracetam - 250
Nu-levetiracetam
Apo-levetiracetam
Levetiracetam ER
Levetiracetam Extended-release
Indication
Levetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older. Additionally, it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older, and in primary generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy who are 6 years of age and older.[L8606] Levetiracetam is also available as an orally dissolvable tablet that is indicated as an adjunct in the treatment of partial onset seizures in patients with epilepsy who are 4 years of age and older and weigh more than 20kg.[L8609]
Categories
Acetamides
Amides
Anticonvulsants
Central Nervous System Agents
Central Nervous System Depressants
Decreased Central Nervous System Disorganized Electrical Activity
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682